Background: MAPK7/ERK5 (extracellular-signal-regulated kinase 5) functions within a canonical three-tiered MAPK (mitogen activated protein kinase) signaling cascade comprising MEK (MAPK/ERK kinase) 5, MEKK(MEK kinase) 2/3 and ERK5 itself. Despite being the least well studied of the MAPK-modules, evidence supports a role for MAPK7-signaling in the pathology of several cancer types. Methods and results: Fluorescence in situ hybridization (FISH) analysis identified MAPK7 gene amplification in 4 % (3/74) of non-small cell lung cancers (NSCLC) (enriched to 6 % (3/49) in squamous cell carcinoma) and 2 % (2/95) of squamous esophageal cancers (sqEC). Immunohistochemical (IHC) analysis revealed a good correlation between MAPK7 gene amplification and protein expression. MAPK7 was validated as a proliferative oncogenic driver by performing in vitro siRNA knockdown of MAPK7 in tumor cell lines. Finally, a novel MEK5/MAPK7 co-transfected HEK293 cell line was developed and used for routine cell-based pharmacodynamic screening. Phosphorylation antibody microarray analysis also identified novel downstream pharmacodynamic (PD) biomarkers of MAPK7 kinase inhibition in tumor cells (pMEF2A and pMEF2D). Conclusions: Together, these data highlight a broader role for dysregulated MAPK7 in driving tumorigenesis within niche populations of highly prevalent tumor types, and describe current efforts in establishing a robust drug discovery screening cascade.
Background
Mitogen activated protein (MAP) kinase signaling pathways are highly evolutionarily conserved throughout eukaryotes and represent a key mechanism in the transduction of intracellular signals. Of the four MAP kinases which exist in mammalian cells (ERK1/2, JNK, p38 and ERK5 [1] [2] [3] , ERK (extracellular-signal-regulated kinase) 5 is the least well studied and most structurally divergent of the family. The ERK5 protein, encoded by the MAPK7 gene [4] , contains an N-terminal kinase domain and a large C-terminal segment, containing a transactivation domain and nuclear localization and export sequences (NLS/NES). ERK5 is the effector kinase of a canonical kinase module containing; MEK (MAPK/ERK kinase) 5, MEKK (MEK kinase) 2/3 and ERK5 itself [5] .
Under normal physiological conditions, MEK5 and ERK5 are activated by growth factors and cellular stresses [6, 7] and, through the use of embryonic gene knockouts of MEK5 or MAPK7, have been shown to contribute largely to blood vessel and cardiac formation during development [8, 9] . In vitro muscle differentiation systems have highlighted prominent roles for ERK5 signaling in muscle development [10] , whilst in adult tissues, the pathway plays a role in regulating the proliferation and survival of endothelial cells and various immune-derived cell populations [11] [12] [13] [14] .
In the context of cancer, clinical evidence suggests a role for dysregulated MEK5/ERK5 signaling as a driver of tumorigenesis in several cancers. Specifically in breast cancer, increased ERK5 protein levels are associated with decreased disease-free survival and furthermore, MEK5 expression is up-regulated by constitutive activation of STAT (signal transducer and activator of transcription) 3, commonly detected in advanced breast cancer [15, 16] . The ERK5 pathway also appears to play a role in mediating chemoresistance in breast cancer cells and contributes to neuregulin signaling in breast cancer cells overexpressing ErbB2 [17, 18] . In prostate cancer, MEK5 is overexpressed and is associated with bone metastases, invasive potential and corresponding poor survival [19] . Furthermore, in hepatocellular carcinoma (HCC), genetic dysregulation of MAPK7 expression through amplification of 17p11 is detectable in around 50 % of primary HCC tumors [20] . In the same study, preclinical validation work using small-interfering RNA (siRNA) suppression of MAPK7 expression in amplified cell lines confirmed a role for dysregulated MAPK7 in controlling mitotic entry.
In the work reported here, we identified genetic dysregulation of MAPK7 and protein overexpression in clinical samples of non-small cell lung cancer (NSCLC) and esophageal cancer (EC) of Asian origin, using array comparative genomic hybridization (aCGH) and FISH (fluorescent in-situ hybridization) technologies. Importantly, by suppressing expression within MAPK7 amplified cell lines, we were able to validate MAPK7 as a driver of tumor cell proliferation and engineer a stable cell line assay for screening of candidate MAPK7 small molecule kinase inhibitors. Lastly, using reverse-phase protein chip arrays, our work identified potential pharmacodynamic biomarkers of MAPK7 kinase inhibition within MAPK7amplified tumor cell lines. In summary, the work here identifies and validates a novel role for dysregulated MAPK7 as a tumor driver in clinical samples of NSCLC and EC, and outlines aspects of preliminary work in developing a drug discovery programme to identify novel small molecule inhibitors of MAPK7 kinase activity.
Results

Identification of dysregulated MAPK7 expression in Chinese squamous cell lung and esophageal carcinoma patient samples
To explore MAPK7 tumor expression profiles in Asian cancer patients, we collected 74 non-small cell lung cancers and 95 squamous esophageal cancers of Chinese origin. Fluorescent in situ hybridization (FISH) analysis identified high level MAPK7 gene amplification in 4 % (3/74) of NSCLC (enriched to 6 % (3/49) in squamous cell carcinoma) and 2 % (2/95) of sqEC ( Fig. 1 and Table 1 ). In order to investigate correlations between genetic dysregulation of MAPK7 expression and corresponding protein expression, immunohistochemical (IHC) analysis of the same NSCLC tissue samples was performed. Analysis revealed that all 3 MAPK7 amplified cases had corresponding high level MAPK7 protein expression (defined as IHC3+), suggesting a good correlation of MAPK7 gene amplification with high level protein expression ( Fig. 2A and Additional file 1: Figure S1 ). Importantly however, this analysis also identified a high prevalence of MAPK7 protein expression in the absence of gene amplification, with 20 % of samples (15/74) staining strongly (IHC3+) for MAPK7 protein expression ( Fig. 2B ). Of the remaining samples, 41 % (30/74), 28 % (21/74) and 11 % (8/74) stained IHC2+, IHC1+ and IHC0 for MAPK7 protein, respectively.
MAPK7 is a driver of tumor cell proliferation in dysregulated cell lines
In order to test the hypothesis that dysregulation of MAPK7 signaling could drive tumor cell proliferation, we undertook a number of studies to explore the functional consequences of silencing MAPK7 gene expression in MAPK7 dysregulated tumor cell lines. Two Fig. 1 Representative FISH data showing MAPK7 gene amplification in NSCLC and sqEC tumor tissues. FISH probes were generated for MAPK7 (red) and internal CEP17 control (green) genes. MAPK7 non-amplified tumor tissue is represented by image LC016, while MAPK7 amplified lung and esophageal tumor tissues are shown in images LC035 and EC012, respectively. Gene amplification criteria were defined as a MAPK7/CEP17 ratio of >2 across at least tumor 50 cells MAPK7 gene amplified and overexpressing cell lines (KYSE30 and SNU449) and a MAPK7 'normal' cell line (NCI-H1793), were selected for study. Detailed MAPK7 gene copy number and MAPK7/CEP17 ratios for these cell lines are tabulated in Additional File 2: Table S1 . FISH staining of cell pellets confirmed MAPK7 gene amplification in cell lines KYSE30 and SNU449, but not in NCI-H1793 ( Fig. 3a) , and Western blotting of lysates confirmed higher level MAPK7 protein expression in KYSE30 and SNU449, but lower levels in NCI-H1793 ( Fig. 3b control lanes and Additional file 3: Figure S2 ). Next, we performed in vitro transfection of these cell lines using MAPK7 small interfering RNA (siRNA) to silence MAPK7 gene expression. Cell lines were transfected over a 4-day period and cell lysates were taken for Western blot analysis of MAPK7 protein expression ( Fig. 3b ). In the MAPK7 dysregulated cell lines KYSE30 and SNU449, MAPK7 protein expression was reduced by 90 and 70 % respectively, using three separate MAPK7 siRNA constructs. In the NCI-H1793 control cell line, despite low baseline MAPK7 protein expression, significant expression knockdown of around 60 % was also achieved. In parallel, and to evaluate the impact of MAPK7 gene silencing on cell proliferation, identical transfection groups were assayed using an Acumenbased 'live/dead' cell enumeration assay over a 6 day period. In the KYSE30 cell line, near complete knockdown of MAPK7 protein expression using all three of the MAPK7 siRNA constructs led to significant reductions in cell proliferation in each case, accompanied by elevations in the numbers of dead cells to between 20 and 40 % after 6 days. In the SNU449 cell line, partial MAPK7 knockdown resulted in significant reductions in the number of live cells after 6 days using 2 of the 3 siRNA constructs, but in this case, with no appreciable change in dead cell counts. Within the NCI-H1793 control cell line, knockdown of MAPK7 protein expression to around 60 % of control levels had no effect on either cell proliferation or cell death. To further confirm these findings, we measured the dynamics of cell line growth over a 6 day period using an Incucyte cell imaging platform. Consistent with the 'live/dead' cell assay, MAPK7 knockdown greatly reduced cell proliferation in KYS30 and SNU449 cell lines, but had no effect on NCI-H1793 ( Fig. 3d ). Two days post-transfection, MAPK7 siRNAtransfected tumor cells failed to follow the same exponential growth dynamics of the control and scrambled siRNA treatment groups, instead displaying suppressed cell growth, and in the case of KYSE30, reductions in the degree of cell confluence consistent with the increased cell death observed in the 'live/dead'cell assay.
Development of a MEK5A/MAPK7 cell-based in vitro pharmacodynamic ELISA co-expression assay for small molecule drug screening
To facilitate drug discovery efforts to target the MAPK7signaling axis, we next sought to develop a cell-based pharmacodynamic assay to enable the effective screening of compounds possessing MAPK7 kinase inhibitory activity. Although previous reports have documented the ability of exogenously added epidermal growth factor (EGF) to induce direct cellular activation of MAPK7, this effect is only reliably detectable using a non-quantitative gel-shift assay [21] . Using a more artificial in vitro system, Kato et al. co-expressed a constitutively active form of MEK5 (MEK5CA) with MAPK7 in CHO-K1 cells and demonstrated the kinase specificity of MEK5 via direct phosphorylation and activation of MAPK7 [22] . Taking a similar approach to ensure robust and specific activation of MAPK7, we generated a stable co-expression system utilizing MEK5CA and MAPK7 within a HEK293 cell background. Western blot analysis demonstrated clear induction of MAPK7 Thr218/Tyr220 phosphorylation by MEK5CA, and importantly, this phosphorylation could be blocked using the commercially available and specific MAPK7 tool compound, XMD8-92 ( Fig. 4a ) [21] . This conclusion was further supported by evidence of a 'gel shift' in the molecular weight of MAPK7 upon coexpression with MEK5CA, indicative of post-translational modifications (likely phosphorylation). Moreover, upon pre-treatment with XMD8-92, this gel-shift did not occur and MAPK7 remained in a lower molecular weight form.
Having achieved a significant and dynamic phospho-MAPK7 signal detectable by Western blot, we next sought to develop a higher throughput ELISA-based phospho-MAPK7 assay. Cell lysates from co-expression studies were tested and optimized in a custom 'sandwich ELISA' assay using commercially available antibodies pairs (described in 'Methods' section), with the results shown in Fig. 4b . High level expression of phosphorylated MAPK7 protein was detectable using the optimized assay platform (lane 4), with an acceptable signal:noise ratio observed upon analysis of XMD8-92 treated cell lysates (lanes 5 and 6). Further validation of this assay was performed using 2 novel small molecules, Gray#18 and Gray#21 (confirmed as MAPK7 kinase inhibitors using a biochemical kinase assay) and 2 unrelated kinase inhibitors, AZD2281 (a PARP inhibitor) and AZD3965 (an MCT1 inhibitor). MAPK7 half-maximal cellular inhibitory concentrations (IC 50 ) were determined for all four agents (Fig. 4c ).
Identification of downstream biomarkers of MAPK7 activity
To enable more comprehensive characterisation of MAPK7-pathway signaling, we sought to identify cellular . Cell lysates were prepared and analysed using Western blot to detect phospho-MAPK7 (T218/Y220), total MAPK7, HA-tag and GAPDH. b Using the same cellular lysates, a quantitative sandwich ELISA assay was developed by coating ELISA plates with a total MAPK7 capture antibody, incubating with lysate and then using a phospho-MAPK7 (T218/Y220) detection antibody. Phospho-MAPK7 signals were then quantified using an envision reader. c Further validation of the pMAPK7 ELISA assay was performed by running dose-response experiments with 4 small molecules; 2 MAPK7 inhibitors and 2 unrelated kinase inhibitors (AZD2281 and AZD3965) pharmacodynamic biomarkers using a reverse-phase protein array (RPPA) platform. Protein extracts were prepared from KYSE30 cells, treated (and untreated) for 2 h with 10 μM XMD8-92, and then applied to the antibody microarray. Quality control and data normalization was performed using a standardized and validated antibody set and actual array chip images are shown in Fig. 5a . Following automated array chip analysis, of 1,318 antibodies (details contained in 'Methods' section) we identified 5 showing significant signal modulation upon treatment with XMD8-92. Compared to untreated control cells, pCDC25C (S216), pCDKN1 (T145), pMEF2A (S408) and pMEF2D (S444) all showed significant reductions with '% of control' values of 39.8, 41.9, 44.7 and 45.1, respectively ( Table 2 ). To corroborate these findings, direct pMEF2A modulation by MAPK7 inhibition was confirmed by immunoblot analysis using an antibody raised against phosphorylated Thr312 of MEF2A (Fig. 5b ).
Discussion
Dysregulated MAPK7 signaling has been demonstrated to play key roles in uncontrolled cell proliferation across several tumor types [15, 17, 19] . The data herein provide a first description of the identification of clinical squamous cell lung and esophageal tumor samples harbouring gene amplified and overexpressed MAPK7. Intriguingly, in addition to the 3 clinical cases showing a correlation between MAPK7 amplification and high level protein expression (IHC3+), we also identified a further 12 cases with IHC3+ protein staining in the absence of MAPK7 amplification, raising the question of whether MAPK7 gene amplification, protein overexpression, or both, are required for driving tumor proliferation. Despite our cell lines showing a good correlation between MAPK7 gene copy number/ ratio and protein expression (Additional file 2: Table S1 and Fig. 3b ), we were unable to fully answer this question with the cell lines and samples available. However, this remains a key question and is a focus of ongoing efforts in a research environment where the development of companion diagnostics for molecularly targeted therapeutic agents is increasingly required to ensure accurate selection of those patients most likely to benefit. Albeit within a relatively small number of lung cancer samples, gene amplification and overexpression of MAPK7 appeared to be a distinct molecular feature, as of the 3 samples, only 1 contained an EGFR L858R mutation and none had KRas mutation (data not shown). Although our data demonstrate coordinate MAPK7 gene amplification and protein overexpression, it should be noted that previous studies have identified additional mechanisms through which MAPK7 activity can be regulated [23, 24] . Detailed exploration of the precise molecular mechanisms of MAPK7 dysregulation was outwith the scope of our work here, however our data do suggest that dysregulated MAPK7 may provide a further level of disease segmentation within squamous cell lung cancer, which crucially, is a disease with high unmet need and currently has no approved targeted therapeutics [25] .
Targeted siRNA knockdown of MAPK7 in two dysregulated cell lines confirmed a driving role for MAPK7 in tumor cell proliferation in vitro. Interestingly, although a good correlation was observed between MAPK7 gene amplification and protein expression in both cell lines, targeted knockdown had slightly different functional effects. Partial knockdown of MAPK7 expression in the SNU449 cell line resulted in anti-proliferative activity but no appreciable increase in cell death above control levels. In contrast, near-complete suppression of MAPK7 A B Fig. 5 Phosphorylation antibody microarray analysis of KYSE30 cells treated with XMD8-92 and confirmation of pMEF2A modulation. a KYSE30 cells were treated (or not) for 2 h with 10 μM XMD8-92 and cell lysates were then prepared and analysed using phospho-antibody microarray. Actual microarray visualizations are presented. b KYSE30 cells were treated for 2 h with a range of XMD8-92 concentrations and cell lysates prepared for Western blotting using antibodies to detect pMEF2A (T312), total MEF2A and GAPDH expression in the KYSE30 cell line resulted in antiproliferative activity and significant increases in cell death above background levels. It is currently unclear whether this difference was attributable to variation in the degree of siRNA MAPK7 suppression, or perhaps due to the cellular background and pathway 'wiring'. Importantly however, significant suppression of MAPK7 expression and a lack of any effect on cell proliferation or cell death in the non-dysregulated MAPK7 cell line, NCI-H1793, confirmed a role for dysregulated MAPK7 in driving uncontrolled cell proliferation. The relatively benign effect of MAPK7 suppression in the MAPK7 'normal' NCI-H1793 cell line is consistent with the results of previous inducible genetic MAPK7 knockout studies in adult mice, which despite perturbing vascular integrity, had no wider effects on the whole animal [11] . To facilitate validation of our cell-based MAPK7 pharmacodynamic ELISA assay and provide a positive control in our biomarker screen, XMD8-92 served as an excellent tool compound due to its highly selective nature. Profiling of this agent against a panel of 402 diverse kinases identified MAPK7 as the most potently inhibited kinase (dissociation constant, K D = 80nM), followed by DCAMKL2 (K D = 190nM), TNK1 (K D = 890nM) and PLK4 (K D = 600nM) [21] . Notably, none of these three kinases are known to have any associations with MAPK7 biology and indeed, perform roles in cellular processes highly distinct to that of MAPK7. Interestingly, and in contrast to the MAPK7 gene knockout work described above, in vivo studies using XMD8-92 did not lead to any vascular abnormalities, supporting the concept that targeting MAPK7 kinase activity (as opposed to whole gene knockout) may be a viable therapeutic strategy. Our identification of MEF2A and MEF2D ('myocyte enhancer factors') as novel pharmacodynamic biomarkers of MAPK7 inhibition is notable. These transcription factors bind and activate the transcription of numerous muscle-specific, growth-factor and stress controlled genes involved primarily in (but not limited to) skeletal and cardiac muscle development. Interestingly however, oncogenic activity has been attributed to MEF2D fusion proteins in acute lymphoblastic leukaemia [26] , underlining a broader role for MAPK7 signaling in oncogenesis. Modulation of CDC25C (pSer216) and CDKN1 (pThr145) indirectly by XMD8-92 treatment are consistent with previously suggested roles for dysregulated MAPK7 in controlling mitotic entry [20] . Although we were able to confirm modulation of MEF2A (pThr312) by XMD8-92 using immunoblot analysis, direct confirmation of the additional biomarkers was not possible due to a lack of high quality antibodies. Efforts are currently ongoing to generate antibody reagents and perform further evaluation.
Conclusions
Taken together, our data provide the first reported incidences of dysregulated MAPK7 expression in clinical samples of squamous cell lung and esophageal carcinoma. Using MAPK7 siRNA, we validate a role for dysregulated MAPK7 in driving cell proliferation in established tumor cell lines and describe the development of a cell based ELISA assay to support screening of novel MAPK7 kinase inhibitors. Finally, we highlight the identification of several putative novel pharmacodynamic biomarkers of cellular MAPK7 signaling. This data affirms MAPK7 as an attractive therapeutic oncology target and outlines aspects of preliminary work in developing a drug discovery program to identify novel small molecule inhibitors of MAPK7 kinase activity.
Methods
Clinical samples and cell lines
74 NSCLC and 95 sqEC cancer clinical samples were collected from Beijing tumor hospital (Beijing, China) with signed patient informed consent. This study was approved by the ethics committee of the Beijing tumor hospital. Cell lines were obtained from commercial sources (American Type Culture Collection, Japan Health Science Research Resource Bank) or from AstraZeneca internal cell banks.
FISH detection
The MAPK7 FISH probe was generated internally by directly labeling BAC (CTD-2387H16) DNA with Spectrum Red (Vysis, Cat # 30-803400). The CEP17-Spectrum Green probe (Vysis, 32-132017) for the centromeric region of chromosome 17 was used as internal control.
FISH assays were performed on 4 μm dewaxed and dehydrated FFPE sections. The SpotLight Tissue pretreatment Kit (Invitrogen, 00-8401) was used for pretreatment (boiled in reagent 1 for~15 min then coated with reagent 2 for~10 min, minor time adjustments were made for individual samples). Sections and probes were codenaturated at 80°C for 5 min and then hybridized at 37°C for 48 h. After a quick post wash off process (0.3 % NP40/1 × SSC at 75.5°C for 5 min, twice in 2 × SSC at room 
Western blotting
Ninety-six h post siRNA transfection, cell lysates were collected and subjected to SDS/PAGE and transferred on to PVDF membrane. The membrane was blocked with 5 % skimmed milk in TBS-Tween20 overnight at 4°C, before being incubated with primary antibody for 2 h at room temperature or overnight at 4°C. After washing, the membrane was incubated with HRP (horseradish peroxidase)-conjugated secondary antibody for 1 h at room temperature. Signals were visualized using Amersham ECL detection reagents (GE health). The primary antibodies included: MAPK7 antibody (CST, #3552), pMAPK7 (T218/Y220) (CST, #3371), pMEF2A (T312) (Abcam, ab#30644), MEF2A (Abcam, ab#32866), and HA (Roche, #11 583 816 001).
Generation of HEK293 cells coexpressing MEK5CA and MAPK7
The constitutively active MEK5 (MEK5CA) and MAPK7 plasmids were constructed as published [22] . HEK293 cells were seeded at 5,000,000/100 ml/T150 flask overnight and then co-transfected with 10 μg MEK5CA and 10 μg MAPK7 by using 60 μl of Roche X-treme Gene 9 DNA transfection reagent (Roche, #6365779001) for 48 h. Cells were then harvested and frozen down in aliquots.
Cell-based pMAPK7 ELISA surrogate PD assay
Co-transfected HEK293 cells (described above) were aliquotted and seeded at a density of 10,000 cells/100 μl/ 96-well for 4 h, and then treated with various concentrations of XMD8-92 for 2 h at 37°C in a cell incubator (Thermo). After washing out cell culture medium, 110 μl/well of RIPA-cocktail buffer was added to lyse the cells overnight. On the same day, 96-well NUNC plates (PerkinElmer, AAAND-0001) were coated with 100 μl/ well of MAPK7 capture antibody (R&D, AF2848) at 1 μg/ml at 4°C overnight. Next day, plates were then washed with buffer (PBS containing 0.05 % Tween20) 3 times, and blocked with 2 % BSA-wash buffer for 1 h. Cell lysates were then added (100 μl/well) for 2 h, followed by washing 3 times. pMAPK7 (T218/Y220) detection antibody (Santa Cruz, sc-135761) was added at 5 μg/ml for 2 h, and plates then washed before incubating with secondary antibody (PerkinElmer, AD0207) for 1 h. Plates were given a final wash, enhancement solution added (PerkinElmer, 1244-104) for 30 min, before reading on the Envision reader(PerkinElmer).
Phosphorylation antibody microarray
The phosphorylation explorer antibody microarray chip PEX100, containing 1,318 well-characterized sitespecific antibodies, was purchased from Full Moon Biosystems (Sunnyvale, CA, USA). Details of these antibodies can be accessed via the vendors website (http:// www.fullmoonbio.com/product/phospho-explorer-antibody-array/). KYSE30 cells (2 × 10 7 cells per 10-cm plate) were treated with or without 10 μM XMD8-92 for 2 h. Cells were washed with cold 1X PBS (4°C) and collected by scraping from the plate. Cells were spun briefly in a microcentrifuge to remove culture media from the cells. Three additional washes were performed using cold 1X PBS (4°C). Cells were centrifuged again at 4°C and supernatant discarded. Cell pellets were shipped to the vendor and antibody microarray's run according to the manufacturer's instruction. Duplicate chips were run for both control and treated lysates groups and '% of control' values calculated according to normalised average plate readings.
